| 1 | Future biomarkers for acute graft-versus-host disease: potential roles of nucleic acids, metabolites, and immune cell markers | 3.1 | 6 | Citations (PDF) |
| 2 | XPO1/Exportin-1 in Acute Myelogenous Leukemia; Biology and Therapeutic Targeting | 4.4 | 1 | Citations (PDF) |
| 3 | Proteomic Comparison of Acute Myeloid Leukemia Cells and Normal CD34+ Bone Marrow Cells: Studies of Leukemia Cell Differentiation and Regulation of Iron Metabolism/Ferroptosis | 3.5 | 4 | Citations (PDF) |
| 4 | The Rac1-inhibitor EHop-016 attenuates AML cell migration and enhances the efficacy of daunorubicin in MOLM-13 transplanted zebrafish larvae | 3.7 | 5 | Citations (PDF) |
| 5 | Monocytic Differentiation of Human Acute Myeloid Leukemia Cells: A Proteomic and Phosphoproteomic Comparison of FAB-M4/M5 Patients with and without Nucleophosmin 1 Mutations | 4.5 | 3 | Citations (PDF) |
| 6 | A woman in her thirties with dyspnoea two weeks after abdominoplasty | 0.1 | 1 | Citations (PDF) |
| 7 | Monocytic Differentiation in Acute Myeloid Leukemia Cells: Diagnostic Criteria, Biological Heterogeneity, Mitochondrial Metabolism, Resistance to and Induction by Targeted Therapies | 4.5 | 13 | Citations (PDF) |
| 8 | The prognostic impact of C‐reactive protein and albumin in patients diagnosed with acute myeloid leukaemia | 1.6 | 0 | Citations (PDF) |
| 9 | Patients with Bacterial Sepsis Are Heterogeneous with Regard to Their Systemic Lipidomic Profiles | 3.5 | 6 | Citations (PDF) |
| 10 | Systemic Metabolomic Profiles in Adult Patients with Bacterial Sepsis: Characterization of Patient Heterogeneity at the Time of Diagnosis | 4.4 | 7 | Citations (PDF) |
| 11 | VEXAS Syndrome in a Patient with Myeloproliferative Neoplasia | 0.3 | 6 | Citations (PDF) |
| 12 | Better and safer allogeneic stem cell transplantation | 0.1 | 0 | Citations (PDF) |
| 13 | Pretransplant systemic metabolic profiles in allogeneic hematopoietic stem cell transplant recipients - identification of patient subsets with increased transplant-related mortality | 2.0 | 8 | Citations (PDF) |
| 14 | The Regulation of Neutrophil Migration in Patients with Sepsis: The Complexity of the Molecular Mechanisms and Their Modulation in Sepsis and the Heterogeneity of Sepsis Patients | 4.8 | 26 | Citations (PDF) |
| 15 | Platelets for advanced drug delivery in cancer | 4.7 | 12 | Citations (PDF) |
| 16 | Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia | 4.0 | 12 | Citations (PDF) |
| 17 | Tuberculosis-Associated Hemophagocytic Lymphohistiocytosis: A Review of Current Literature | 2.6 | 23 | Citations (PDF) |
| 18 | Vacuolar ATPase Is a Possible Therapeutic Target in Acute Myeloid Leukemia: Focus on Patient Heterogeneity and Treatment Toxicity | 2.6 | 8 | Citations (PDF) |
| 19 | Iron Status and Physical Performance in Athletes | 2.8 | 33 | Citations (PDF) |
| 20 | En mann i 40-årene med transfusjonskrevende anemi | 0.1 | 0 | Citations (PDF) |
| 21 | Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature | 3.1 | 3 | Citations (PDF) |
| 22 | Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia | 4.3 | 21 | Citations (PDF) |
| 23 | An Abrupt Transition to Digital Teaching—Norwegian Medical Students and Their Experiences of Learning Output during the Initial Phase of the COVID-19 Lockdown | 2.3 | 6 | Citations (PDF) |
| 24 | Hematopoiesis, Inflammation and Aging—The Biological Background and Clinical Impact of Anemia and Increased C-Reactive Protein Levels on Elderly Individuals | 2.6 | 22 | Citations (PDF) |
| 25 | Endocan in Acute Leukemia: Current Knowledge and Future Perspectives | 4.4 | 4 | Citations (PDF) |
| 26 | Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis | 3.1 | 2 | Citations (PDF) |
| 27 | MicroRNA serum profiles and chronic graft-versus-host disease | 5.3 | 15 | Citations (PDF) |
| 28 | Concomitant Hemophagocytic Lymphohistiocytosis and Cytomegalovirus Disease: A Case Based Systemic Review | 2.6 | 19 | Citations (PDF) |
| 29 | Når blodet flyter langsomt | 0.1 | 0 | Citations (PDF) |
| 30 | Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients | 4.0 | 5 | Citations (PDF) |
| 31 | NPM1-Mutated Patient-Derived AML Cells Are More Vulnerable to Rac1 Inhibition | 3.5 | 5 | Citations (PDF) |
| 32 | Eksamensformer i de norske medisinstudiene | 0.1 | 0 | Citations (PDF) |
| 33 | Limbic Encephalitis following Allogeneic Hematopoietic Stem Cell Transplantation | 1.1 | 1 | Citations (PDF) |
| 34 | Musculoskeletal Chronic Graft versus Host Disease—A Rare Complication to Allogeneic Hematopoietic Stem Cell Transplant: A Case-Based Report and Review of the Literature | 3.1 | 5 | Citations (PDF) |
| 35 | Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition | 4.5 | 5 | Citations (PDF) |
| 36 | Trombocytopeni hos kritisk syke pasienter | 0.1 | 0 | Citations (PDF) |
| 37 | Spontaneous Splenic Artery Rupture as the First Symptom of Systemic Amyloidosis | 0.5 | 2 | Citations (PDF) |
| 38 | Carbapenem-Resistant Enterobacteriaceae—Implications for Treating Acute Leukemias, a Subgroup of Hematological Malignancies | 4.2 | 5 | Citations (PDF) |
| 39 | p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy | 4.8 | 6 | Citations (PDF) |
| 40 | Immunoglobulin-Storing Histiocytosis: A Case Based Systemic Review | 2.6 | 16 | Citations (PDF) |
| 41 | Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid | 4.0 | 11 | Citations (PDF) |
| 42 | Platelet Microparticles Protect Acute Myelogenous Leukemia Cells against Daunorubicin-Induced Apoptosis | 4.0 | 24 | Citations (PDF) |
| 43 | Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia—Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation | 4.4 | 7 | Citations (PDF) |
| 44 | Hyperferritinemia—A Clinical Overview | 2.6 | 102 | Citations (PDF) |
| 45 | Kidney Failure and Abdominal Discomfort as Initial Signs of Extramedullary Acute Myelogenous Leukemia | 2.2 | 1 | Citations (PDF) |
| 46 | HFE Genotype, Ferritin Levels and Transferrin Saturation in Patients with Suspected Hereditary Hemochromatosis | 2.6 | 8 | Citations (PDF) |
| 47 | Effects of the Autophagy-Inhibiting Agent Chloroquine on Acute Myeloid Leukemia Cells; Characterization of Patient Heterogeneity | 2.6 | 19 | Citations (PDF) |
| 48 | Proteomic Characterization of Spontaneous Stress-Induced In Vitro Apoptosis of Human Acute Myeloid Leukemia Cells; Focus on Patient Heterogeneity and Endoplasmic Reticulum Stress | 0.9 | 4 | Citations (PDF) |
| 49 | Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation | 0.5 | 0 | Citations (PDF) |
| 50 | Patient Heterogeneity in Acute Myeloid Leukemia: Leukemic Cell Communication by Release of Soluble Mediators and Its Effects on Mesenchymal Stem Cells | 2.8 | 7 | Citations (PDF) |
| 51 | Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences | 2.6 | 51 | Citations (PDF) |
| 52 | En ung kvinne med pustevansker og proteinuri | 0.1 | 0 | Citations (PDF) |
| 53 | Leukemia cutis | 0.1 | 0 | Citations (PDF) |
| 54 | FEBRILE NEUTROPENIA IN ACUTE LEUKEMIA. EPIDEMIOLOGY, ETIOLOGY, PATHOPHYSIOLOGY AND TREATMENT | 0.8 | 73 | Citations (PDF) |
| 55 | Inhibition of NF-κB Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics | 4.8 | 20 | Citations (PDF) |
| 56 | Surgical Treatment of Severe Bowel Obstruction as a Rare Complication Following Allogenic Hematopoietic Stem Cell Transplantation | 0.5 | 0 | Citations (PDF) |
| 57 | Hemophagocytic lymphohistiocytosis and miliary tuberculosis in a previously healthy individual: a case report | 0.9 | 14 | Citations (PDF) |
| 58 | Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy | 0.4 | 1 | Citations (PDF) |
| 59 | Targeting Cellular Metabolism in Acute Myeloid Leukemia and the Role of Patient Heterogeneity | 4.8 | 33 | Citations (PDF) |
| 60 | Critical Upper Airway Obstruction as the First Symptom of Acute Myeloid Leukemia—An Anesthesiologic Reminder | 2.2 | 3 | Citations (PDF) |
| 61 | Pure Red Cell Aplasia with Del(20q) Sensitive for Immunosuppressive Treatment | 0.3 | 2 | Citations (PDF) |
| 62 | The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells | 4.5 | 280 | Citations (PDF) |
| 63 | A patient with maculopapular rash and lichenoid skin damage caused by ponatinib | 1.4 | 5 | Citations (PDF) |
| 64 | Covid-19 og venøs tromboembolisme – profylakse og behandling | 0.1 | 0 | Citations (PDF) |
| 65 | Hyperferritinemi-katarakt-syndrom | 0.1 | 0 | Citations (PDF) |
| 66 | Precision medicine for TP53-mutated acute myeloid leukemia | 0.8 | 2 | Citations (PDF) |
| 67 | High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype | 2.6 | 27 | Citations (PDF) |
| 68 | Mondor’s disease after extensive training with Nordic walking | 0.5 | 2 | Citations (PDF) |
| 69 | Trisomy 8 in acute myeloid leukemia | 2.0 | 44 | Citations (PDF) |
| 70 | Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells | 43.9 | 64 | Citations (PDF) |
| 71 | Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults | 3.6 | 16 | Citations (PDF) |
| 72 | En mann i 70-årene med ryggsmerter, mageplager og utslett | 0.1 | 0 | Citations (PDF) |
| 73 | Behandling av akutt myelogen leukemi hos eldre | 0.1 | 0 | Citations (PDF) |
| 74 | En kvinne i 40-årene med bekkensmerter og uklare MR-funn | 0.1 | 0 | Citations (PDF) |
| 75 | Severe Nephritis as Initial Sign of Waldenström’s Macroglobulinemia | 2.2 | 0 | Citations (PDF) |
| 76 | Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia | 3.6 | 37 | Citations (PDF) |
| 77 | The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis | 1.9 | 5 | Citations (PDF) |
| 78 | Successful eradication of leptomeningeal plasma cell disease | 0.5 | 2 | Citations (PDF) |
| 79 | Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation | 0.3 | 3 | Citations (PDF) |
| 80 | Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis | 4.0 | 35 | Citations (PDF) |
| 81 | Cytokine profiling and post‐transfusion haemoglobin increment in patients with haematological diseases | 1.2 | 8 | Citations (PDF) |
| 82 | Myeloid Sarcoma after Allogenic Stem Cell Transplantation for Acute Myeloid Leukemia: Successful Consolidation Treatment Approaches in Two Patients | 0.3 | 6 | Citations (PDF) |
| 83 | Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers | 5.1 | 21 | Citations (PDF) |
| 84 | Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis | 2.6 | 58 | Citations (PDF) |
| 85 | The Possible Importance of β3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia | 4.5 | 46 | Citations (PDF) |
| 86 | Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism | 4.5 | 24 | Citations (PDF) |
| 87 | Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison | 3.7 | 16 | Citations (PDF) |
| 88 | Gelatinøs benmarg | 0.1 | 0 | Citations (PDF) |
| 89 | Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment | 3.1 | 28 | Citations (PDF) |
| 90 | Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism | 3.7 | 27 | Citations (PDF) |
| 91 | Therapeutic targeting of leukemic stem cells in acute myeloid leukemia – the biological background for possible strategies | 4.3 | 34 | Citations (PDF) |
| 92 | Microcirculation and red cell transfusion in patients with sepsis | 0.9 | 16 | Citations (PDF) |
| 93 | Non-curative surgery for aortoenteric fistula | 0.5 | 6 | Citations (PDF) |
| 94 | CDC25 Inhibition in Acute Myeloid Leukemia–A Study of Patient Heterogeneity and the Effects of Different Inhibitors | 4.3 | 12 | Citations (PDF) |
| 95 | Altered Immune Activation and IL-23 Signaling in Response to Candida albicans in Autoimmune Polyendocrine Syndrome Type 1 | 5.1 | 14 | Citations (PDF) |
| 96 | Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells | 3.1 | 23 | Citations (PDF) |
| 97 | Ei ung kvinne med brystsmerter og dyspné | 0.1 | 0 | Citations (PDF) |
| 98 | Ringsideroblaster | 0.1 | 0 | Citations (PDF) |
| 99 | A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators | 5.1 | 27 | Citations (PDF) |
| 100 | Pretransplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation | 4.5 | 36 | Citations (PDF) |
| 101 | How should quality of life assessment be integrated in the evaluation of patients with acute myeloid leukemia? | 1.1 | 3 | Citations (PDF) |
| 102 | Dysmorfe plasmaceller i blod | 0.1 | 1 | Citations (PDF) |
| 103 | Myeloproliferative neoplasiar og JAK2-mutasjonar | 0.1 | 2 | Citations (PDF) |
| 104 | Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid LeukemiaBlood, 2016, 128, 3995-3995 | 4.2 | 1 | Citations (PDF) |
| 105 | Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation | 1.7 | 15 | Citations (PDF) |
| 106 | The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells | 0.6 | 56 | Citations (PDF) |
| 107 | The importance of sample collection when using single cytokine levels and systemic cytokine profiles as biomarkers — a comparative study of serum versus plasma samples | 1.5 | 22 | Citations (PDF) |
| 108 | Altered plasma levels of cytokines, soluble adhesion molecules and matrix metalloproteases in venous thrombosis | 2.4 | 47 | Citations (PDF) |
| 109 | Effects of cytarabine on activation of human T cells – cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid | 2.7 | 27 | Citations (PDF) |
| 110 | The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation | 2.8 | 37 | Citations (PDF) |
| 111 | Nutrition in Allogeneic Stem Cell Transplantion - Clinical Guidelines and Immunobiological Aspects | 2.2 | 9 | Citations (PDF) |
| 112 | Plasmaceller med inklusjonar | 0.1 | 1 | Citations (PDF) |
| 113 | Single Cell-Level Signaling Profiling of Acute Myeloid Leukemia Following Treatment with Axl Kinase Inhibitor BGB324Blood, 2015, 126, 4931-4931 | 4.2 | 0 | Citations (PDF) |
| 114 | Preconditioning Serum Levels of Endothelial Cell-Derived Molecules and the Risk of Posttransplant Complications in Patients Treated with Allogeneic Stem Cell Transplantation | 1.7 | 16 | Citations (PDF) |
| 115 | Therapeutic Targeting the Cell Division Cycle 25 (CDC25) Phosphatases in Human Acute Myeloid Leukemia — The Possibility to Target Several Kinases through Inhibition of the Various CDC25 Isoforms | 4.3 | 78 | Citations (PDF) |
| 116 | Bacterial contamination of blood components: Norwegian strategies in identifying donors with higher risk of inducing septic transfusion reactions in recipients | 0.9 | 30 | Citations (PDF) |
| 117 | Antileukaemic effect of <scp>PI</scp>3<scp>K</scp>‐m<scp>TOR</scp> inhibitors in acute myeloid leukaemia‐gene expression profiles reveal <scp>CDC</scp>25<scp>B</scp> expression as determinate of pharmacological effect | 2.4 | 37 | Citations (PDF) |
| 118 | Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis | 1.5 | 23 | Citations (PDF) |
| 119 | Identification of a subset of patients with acute myeloid leukemia characterized by long-term<i>in vitro</i>proliferation and altered cell cycle regulation of the leukemic cells | 3.7 | 25 | Citations (PDF) |
| 120 | Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies | 4.8 | 35 | Citations (PDF) |
| 121 | Akutt promyelocyttleukemi | 0.1 | 2 | Citations (PDF) |
| 122 | The Possible Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicine—The Experience in Acute Myeloid Leukemia from Disease Development and Diagnosis via Conventional Chemotherapy to Allogeneic Stem Cell Transplantation | 3.9 | 32 | Citations (PDF) |
| 123 | Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors | 3.6 | 29 | Citations (PDF) |
| 124 | Targeted Anti-leukemic Therapy as Disease-stabilizing Treatment for Acute Myeloid Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will it be Possible to Combine these Strategies with Retransplantation or Donor Lymphocyte Infusions? | 2.5 | 10 | Citations (PDF) |
| 125 | Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells | 1.7 | 44 | Citations (PDF) |
| 126 | Tidleg trombocyttransfusjon ved akutt leukemi er best | 0.1 | 0 | Citations (PDF) |
| 127 | Survival Stratification In Acute Myeloid Leukemia By Single Cell Signal ProfilingBlood, 2013, 122, 2625-2625 | 4.2 | 1 | Citations (PDF) |
| 128 | The angioregulatory cytokine network in human acute myeloid leukemia – from leukemogenesis via remission induction to stem cell transplantation | 1.2 | 46 | Citations (PDF) |
| 129 | The effects of selective serotonin reuptake inhibitors on platelet function in whole blood and platelet concentrates | 2.4 | 18 | Citations (PDF) |
| 130 | The Pretransplantation Serum Cytokine Profile in Allogeneic Stem Cell Recipients Differs from Healthy Individuals, and Various Profiles are Associated with Different Risks of Posttransplantation Complications | 1.6 | 36 | Citations (PDF) |
| 131 | Soluble mediators released by acute myeloid leukemia cells increase capillary‐like networks | 1.9 | 21 | Citations (PDF) |
| 132 | Questionnaire-Related Deferrals in Regular Blood Donors in Norway | 1.0 | 6 | Citations (PDF) |
| 133 | Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with <i>FLT3</i> mutation status – consequences and potentials for pharmacological intervention | 2.4 | 39 | Citations (PDF) |
| 134 | Disease‐stabilizing treatment with all‐trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti‐leukemic treatment | 6.1 | 37 | Citations (PDF) |
| 135 | En mann med smerter etter kneoperasjon | 0.1 | 0 | Citations (PDF) |
| 136 | A prospective observational study of the effect of platelet transfusions on levels of platelet-derived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia | 1.2 | 17 | Citations (PDF) |
| 137 | Untangling the intracellular signalling network in cancer — A strategy for data integration in acute myeloid leukaemia | 2.4 | 6 | Citations (PDF) |
| 138 | Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications | 2.7 | 77 | Citations (PDF) |
| 139 | Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation | 1.9 | 54 | Citations (PDF) |
| 140 | Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release | 3.6 | 40 | Citations (PDF) |
| 141 | Thrombelastography | 0.9 | 143 | Citations (PDF) |
| 142 | Nuclear Factor-κB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia | 0.9 | 48 | Citations (PDF) |
| 143 | Granulocyttransfusjon | 0.1 | 1 | Citations (PDF) |
